Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Pérez-Lamas, Lucía
• dc.contributor.author Segura Díaz, Adrián
• dc.contributor.author Mora Casterá, Elvira
• dc.contributor.author Hidalgo Soto, Marta
• dc.contributor.author Paz Coll, Antonio
• dc.contributor.author De Las Heras, Natalia
• dc.contributor.author Cortes, Montse
• dc.contributor.author Vélez Tenza, Patricia
• dc.contributor.author Sierra Pacho, Magdalena
• dc.contributor.author Senín Magan, Maria Alicia
• dc.contributor.author Angona Figueras, Anna
• dc.contributor.author Cervero, Carlos
• dc.contributor.author De Paz, Raquel
• dc.contributor.author Salamanca Cuenca, Araceli
• dc.contributor.author Santaliestra, Marta
• dc.contributor.author López Marín, Javier
• dc.contributor.author Casado-Montero, Luis Felipe
• dc.contributor.author García-Gutiérrez, Valentín
• dc.date.accessioned 2025-09-29T12:34:56Z
• dc.date.available 2025-09-29T12:34:56Z
• dc.date.issued 2024
• dc.description.abstract Patients with chronic myeloid leukemia (CML) who have failed conventional tyrosine kinase inhibitors (cTKIs) and asciminib constitute a complex group of patients with few therapeutic options. A retrospective descriptive multicenter observational study was carried out including patients with CML who had presented a therapeutic failure to ≥ 2 cTKIs and asciminib, and had received or were not candidates to ponatinib. Of the 19 patients enrolled, 8 patients failed asciminib due to intolerance and 11 due to resistance. The most common strategy for intolerant patients was to initiate a previously administered cTKI (6/8) with dose adjustments or symptomatic management of adverse events (AEs). Of the patients who failed due to resistance, only patients who underwent progenitor transplantation achieved profound long-term responses. A frequent strategy was to use ponatinib (4/11) in patients previously considered non-candidates, with poor responses in patients in whom dose reductions were used, and severe AEs in patients at standard doses. In the remaining patients, cTKIs and other agents (interferon, hydroxyurea, citarabine, busulfan) were used with poor responses. Patients who progressed to advanced stages had a dismal prognosis. With a median follow-up of 11.2 months, overall survival of the global cohort was 73%; 100% for intolerant patients, 71% for resistant patients and 25% for those who discontinue asciminib in accelerated/blastic phase.
• dc.format.mimetype application/pdf
• dc.identifier.citation Pérez-Lamas L, Díaz AS, Casterá EM, Soto MH, Coll AP, De Las Heras N, et al. Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib. Ann Hematol. 2024 Nov;103(11):4537-44. DOI: 10.1007/s00277-024-05906-6
• dc.identifier.doi http://dx.doi.org/10.1007/s00277-024-05906-6
• dc.identifier.issn 0939-5555
• dc.identifier.uri http://hdl.handle.net/10230/71287
• dc.language.iso eng
• dc.publisher Springer
• dc.relation.ispartof Ann Hematol. 2024 Nov;103(11):4537-44
• dc.rights © The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
• dc.subject.keyword Asciminib
• dc.subject.keyword Chronic myeloid leukemia
• dc.subject.keyword Conventional tyrosine kinase inhibitors
• dc.subject.keyword Intolerance
• dc.subject.keyword Real world setting
• dc.subject.keyword Resistance
• dc.title Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion